**COLORECTAL CANCER**

The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma

A Conlin, G Smith, F A Carey, C R Wolf, R J C Steele

**Background:** Accumulation of molecular alterations, including mutations in Kirsten-ras (K-ras), p53, and adenomatous polyposis coli (APC), contribute to colorectal carcinogenesis. Our group has previously characterised a panel of sporadic colorectal adenocarcinomas for mutations in these three genes and has shown that p53 and K-ras mutations rarely occur in the same colorectal tumour. This suggests that mutations in these genes are on separate pathways to colorectal cancer development and may influence patient prognosis independently.

**Aims:** To correlate the presence or absence of mutations in K-ras, p53, and APC with survival in a cohort of colorectal cancer patients.

**Patients:** A series of 107 inpatients treated surgically for colorectal cancer in Tayside, Scotland between November 1997 and December 1999.

**Methods:** Colorectal tumours were characterised for mutations in K-ras, p53, and APC. Kaplan-Meier survival curves were constructed using overall survival and disease specific survival as the primary end points. Patient survival was analysed using the log rank test and Cox proportional hazards model.

**Results:** Patients with K-ras mutations had significantly poorer overall survival than patients without K-ras mutations ($p = 0.0098$). Multivariate analysis correcting for Dukes’ stage, age, and sex confirmed this (hazard ratio 2.9 (95% confidence interval 1.4–6.2); $p = 0.0040$). K-ras mutations were also significantly associated with poorer disease specific survival. The presence of APC and p53 mutations did not affect survival in this cohort of patients ($p = 0.9034$ and $p = 0.8290$, respectively).

**Conclusions:** Our data indicate that the presence of the mutations in these genes predicts poor patient prognosis in colorectal cancer, independently of tumour stage.

Colorectal cancer is a significant cause of morbidity and mortality in the developed world with over 30 000 new cases diagnosed annually in the UK. Although patients diagnosed with early stage disease have a high cure rate, many present later when five year survival is poor. It has long been recognised that colorectal carcinogenesis is a multistep process involving accumulation of molecular alterations and it has also been suggested that associations may exist between many of these abnormalities and patient survival.

Increased understanding of the changes in specific molecular pathways that are responsible for disease progression and poor prognosis may prove essential in the development of more effective targeted treatment.

It has been suggested that progression from benign colorectal adenoma to malignant carcinoma arises from an accumulation of several events, including chromosomal abnormalities, genetic mutations, and epigenetic changes.

These changes result in inactivation of tumour suppressor genes and DNA mismatch repair genes or activation of oncogenes. Mutation of the genes adenomatous polyposis coli (APC), Kirsten-ras (K-ras), and p53 are thought to be critical in the development of colorectal cancer.

APC is a tumour suppressor gene encoding a large 312 kDa protein with an important role in the wnt signalling pathway, intercellular adhesion, cytoskeleton stabilisation, cell cycle regulation, and apoptosis. Inactivating, predominantly truncating, mutations of APC are thought to allow unregulated transcription of oncogenes such as c-myc and cyclin D1, therefore promoting tumorigenesis.

The p53 tumour suppressor gene encodes a nuclear phosphoprotein with the ability to bind directly to DNA and act as a transcriptional activator. Genes activated by p53 cause cell cycle arrest allowing a damaged cell to either repair itself or be targeted for apoptosis. Mutations of the p53 gene are among the commonest genetic alterations in all cancers.

K-ras is part of a group of three highly homologous oncogenes and encodes a small 21 kDa protein (p21ras) involved in transduction of external stimuli to effector molecules across plasma membranes. This protein has intrinsic GTPase activity, allowing inactivation following signal transduction in the normal cellular environment. Activating mutations of K-ras occurring early in colorectal tumorigenesis are thought to abolish GTPase activity, leading to increased and unregulated cellular proliferation and malignant transformation.

Our group has characterised a consecutive cohort of 107 colorectal adenocarcinomas for mutations in APC, K-ras, and p53 showing that simultaneous mutations in all three genes was uncommon in the same tumour and, in particular, mutations in p53 and K-ras rarely occurred together (fig 1). This has important implications as it suggests that K-ras and p53 mutations are on separate pathways to colorectal tumorigenesis and are not part of a common pathway of accumulating genetic change. Although K-ras mutations in colorectal cancer have been associated with poor prognosis in several publications, including a large multicentre study, the literature on p53 mutations and prognosis is controversial, with some studies reporting a link with poor prognosis and some reporting no association.

We have completed a follow up database of this patient cohort and analysed K-ras, p53, and APC mutations in association with survival. To the best of our knowledge, this is the first study to examine the relationship between patient survival and these genes.

**Abbreviations:** K-ras, Kirsten-ras; APC, adenomatous polyposis coli; MCR, mutation cluster region; HR, hazard ratio
prognosis and mutations in K-ras, p53, and APC in a single cohort of colorectal cancer patients.

METHODS

Patients

Patients undergoing surgery for colorectal cancer at Ninewells Hospital, Dundee, or Perth Royal Infirmary between November 1997 and December 1999 were enrolled in this study. All participants were Caucasian, aged 45–80 years, and did not have a previous history of cancer. There were 42 female and 65 male patients. This study was approved by the Tayside Committee for Medical Research Ethics.

Samples

Resected colon specimens were transported directly from theatre to the pathology department and examined by a consultant pathologist (FAC) who selected normal and tumour tissue samples. A total of 107 samples were stored in liquid nitrogen for later analysis. DNA was extracted, amplified, and sequenced from fresh frozen tumour tissue, as described below.

Mutation detection

Genomic DNA was extracted from each tumour tissue sample and regions of each gene were amplified using specific oligonucleotide primers. Specifically, the mutation cluster region (MCR) of APC, codons 12, 13, and 61 of K-ras, and the entire coding region of p53 were examined. Over 60% of all somatic mutations in APC occur within the MCR (codons 1286–1513) and most K-ras mutations occur at codon 12, 13, or 61. Although most mutations in p53 occur within exons 5–8 at “hotspot” codons 175, 245, 248, and 273, the MCR is less well characterised so the entire coding region was analysed. Mutation detection was carried out using a combination of denaturing high performance liquid chromatography and direct DNA sequencing. These methods have been previously described in detail.18

Statistics

Kaplan-Meier survival curves were constructed for overall and disease specific survival and the log rank test was used to evaluate differences between survival curves of patients with and without genetic mutations. Survival was defined as the time from the date of diagnosis of colorectal cancer to the date of death. Multivariate analysis was carried out using the Cox proportional hazards model with hazard ratios (HRs) and 95% confidence intervals (CI) being calculated for each model. Models correcting for disease stage (Dukes’ stage), patient age at diagnosis, and sex were developed. Dukes’ stage was treated as a categorical variable with each stage compared relative to Dukes’ A. All analyses were carried out using the Statistical Package for the Social Services (SPSS) software package (Chicago, Illinois, USA).

RESULTS

Clinical information on 107 patients was entered into the follow up database (table 1). Minimum and maximum follow up periods were 55 and 81 months, respectively, with a mean colorectal cancer patient survival of 58 months.

Analysis of the 107 tumours revealed mutation frequencies in p53 of 61%, APC of 56%, and K-ras of 27%, as previously reported.18 These results are consistent with literature reports showing that APC was mutated in 50–83% of sporadic colorectal cancers,22–24 p53 was mutated in 41–69%,362 5 and K-ras was mutated in 20–38%.26–29 Only 6% of tumours contained mutations in all three genes and mutations in both p53 and K-ras rarely occurred (fig 1). Most p53 mutations occurred in exons 5–8 and most APC mutations were frame shifts introducing a premature stop codon; 79% (n = 23) of K-ras mutations occurred in codon 12 and 21% (n = 6) in codons 13 or 61.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Patient clinical characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristic</td>
<td>Female</td>
</tr>
<tr>
<td>No of patients</td>
<td>42</td>
</tr>
<tr>
<td>Age (median (range))</td>
<td>69 (46–80)</td>
</tr>
<tr>
<td>Dukes’ stage</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>4</td>
</tr>
<tr>
<td>B</td>
<td>15</td>
</tr>
<tr>
<td>C</td>
<td>20</td>
</tr>
<tr>
<td>D</td>
<td>3</td>
</tr>
<tr>
<td>Tumour localisation</td>
<td></td>
</tr>
<tr>
<td>Right side</td>
<td>5</td>
</tr>
<tr>
<td>Left side</td>
<td>20</td>
</tr>
<tr>
<td>Rectal</td>
<td>17</td>
</tr>
<tr>
<td>Patients alive at last follow up</td>
<td>25</td>
</tr>
<tr>
<td>Patients dead at last follow up</td>
<td>17</td>
</tr>
<tr>
<td>Cause of death</td>
<td></td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>15</td>
</tr>
<tr>
<td>Other</td>
<td>1</td>
</tr>
<tr>
<td>Unknown</td>
<td>1</td>
</tr>
</tbody>
</table>
K-ras, p53 and APC mutations in colorectal carcinoma

DISCUSSION

Our group has characterised a large panel of colorectal cancers for mutations in APC, p53, and K-ras and shown that mutations in all three genes occurred uncommonly in the same colorectal tumour and that p53 and K-ras mutations rarely coexisted in the same tumour.18 This suggests that mutations in these genes are on separate pathways in colorectal tumorigenesis. We have now studied the clinical implications of these specific molecular changes in the original patient cohort and established that p53 and APC mutations do not affect survival. However, patients who have a K-ras mutation in their colorectal tumour have a significantly poorer prognosis than those without a K-ras mutation. A large proportion of patients with a K-ras mutation presented with late stage disease, and therefore to ensure that the prognostic effect associated with K-ras mutation was not just a reflection of this later stage disease, we carried out a multivariate analysis. We developed models correcting for disease stage, age, and sex and analysed the data using Cox regression. This confirmed that the presence of K-ras mutations was an independent adverse prognostic variable using overall and disease specific survival as primary end points. A multicentre study showed that only one of the 12 possible K-ras mutations appeared to infer poor prognosis in colorectal cancer.19 It was not possible to accurately assess the effect of specific K-ras mutations on survival in our patient cohort due to the small patient numbers in each group.

Mutated K-ras is constitutively active and we hypothesise that this may cause increased and unregulated signalling down pathways normally involved in growth and differentiation such as the mitogen activated kinase pathway.30 Our data suggest that K-ras mutation is a marker of aggressive tumour phenotype, and therefore detecting this mutation at an earlier disease stage may be of importance. This could also have significant implications for treatment, as patients with K-ras mutations often undergo surgery with curative intent but are not routinely offered adjuvant therapy.11 Patients with early stage disease and a K-ras mutation in their tumour may benefit from an alternative more aggressive treatment regimen.

Randomised controlled trials and pilot programmes have demonstrated that screening with guaiac based faecal occult blood testing reduces disease specific mortality and is feasible.
within the UK National Health Service. A national colorectal cancer screening programme is to be implemented and will increase the proportion of the population with Dukes’ stage A and B cancers. It is inevitable that some of the screen detected early stage cancers will have an aggressive phenotype and more sophisticated measurements of tumour behaviour will be required in order to utilise adjuvant treatment in an appropriate manner. Our data suggest that mutation detection may provide information that could allow tailoring of treatment in a situation where Dukes’ staging may be misleading. K-ras appears to be a suitable candidate gene requiring further evaluation in this context.

An important aspect of this study is that for the first time we have analysed all three major gene mutations in colorectal cancer in relation to prognosis in a single patient cohort. The results of this study would indicate that, while APC and p53 mutations do not have clinical significance, mutation of K-ras defines a subgroup of cancers that arise independently of p53 mutation, tend to be of advanced stage at presentation, and are associated with an adverse prognosis at all disease stages.

ACKNOWLEDGEMENTS
This work was completed with funding from the Food Standards Agency (contracts TO1004 and TO1022) and in collaboration with “The Colorectal Cancer Study Group”[34].

Authors’ affiliations
A Conlin, Biomedical Research Centre, Ninewells Hospital and Medical School, Dundee, UK
G Smith, Biomedical Research Centre, University of Dundee, Dundee, UK
F A Carey, Department of Pathology, University of Dundee, UK
C R Wolf, CRUK Molecular Pharmacology Unit, Biomedical Research Centre, University of Dundee, Dundee, UK
R J C Steele, Departments of Surgery and Molecular Oncology, University of Dundee, Dundee, UK

Conflict of interest: None declared.

REFERENCES
12. Morrison EE, Wardleworth BN, Asham JM, et al. EB1, a protein which interacts with the APC tumour suppressor, is associated with the microtubule cytoskeleton throughout the cell cycle. Oncogene 1999;18:3471–7.